Clinical trials: Metastatic Malignant Neoplasm to Brain
Brain Metastases
Volumetric Modulated Arc Therapy (VMAT) for Brain Metastases
Radiotherapy to the whole brain is standard treatment for cancer that has spread to the brain (brain metastases) as it treats both the metastases that can be seen on scans and the brain metastases that are too small to be seen on…
- Trial name
- NCT01046123
- Testing
- whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Breast Cancer
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
- Trial name
- DB-07 (NCT04538742)
- Testing
- Trastuzumab deruxtecan, Durvalumab, Paclitaxel
- Where
- 72 sites in United States, Australia and 13 more
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
NSCLC
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
EGFR mutation-positive NSCLC patients have a higher risk of developing brain metastases. The prognosis is poor for patients presenting with brain or leptomeningeal metastases at any stage, particularly those with such metastases…
- Trial name
- NCT06945705
- Testing
- furmonertinib combined with anlotinib
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Henan Cancer Hospital
Metastatic Malignant Neoplasm to Brain
Neurocognitive Outcome of Conformal WBRT w/wo Hippocampal Avoidance for Brain Metastases
Brain metastases are the most common brain tumors in adults. It is estimated that around 10-30% of cancer patients would develop brain metastases during the course of their illness.
- Trial name
- NCT02393131
- Testing
- Hippocampal avoidance WBRT, Conformal WBRT
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Brain Metastases
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
This is a single arm, open label trial to assess the safety and efficacy of tucatinib in combination with pembrolizumab and trastuzumab for the treatment of HER2+ breast cancer brain metastases (BCBM).
- Conditions
- Breast Cancer, Brain Metastases, HER2-positive Breast Cancer, CNS Disease
- Trial name
- TOPAZ (NCT04512261)
- Testing
- Tucatinib, Pembrolizumab, Trastuzumab
- Where
- United States
- Sponsor
- Reva Basho
Brain Cancer
Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy
The goal of this clinical research study is to learn if your thinking ability (cognitive function) will be better preserved by delivering whole brain radiation therapy immediately after radiosurgical treatment of 1-3 brain…
- Trial name
- NCT00548756
- Testing
- Whole Brain Radiation Therapy, Observation, Questionnaire
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastasis, SRS
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
The goal of this clinical trial is to evaluate the efficacy of stereotactic radiotherapy in the treatment of brain metastases. The main question it aims to answer is: Did stereotactic radiotherapy improve LC rate in the treatment…
- Trial name
- NCT06852001
- Testing
- X-ray stereotactic radiotherapy for brain metastasis
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Brain Metastases
GliaSite 1-3 Mets Study
This study has been designed to compile information on the efficacy of the GliaSite RTS combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.
- Trial name
- NCT00589212
- Testing
- GliaSite Radiation Therapy System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Hologic, Inc.
Breast Neoplasms, Neoplasm Metastasis
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions…
- Trial name
- NCT01441596
- Testing
- Vinorelbine, Investigator's choice of treatment, afatinib
- Where
- 40 sites in United States, Canada and 6 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Melanoma Brain Metastases
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Single arm phase I/II trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT) in patients with symptomatic melanoma brain…
- Trial name
- BETTER (NCT06163820)
- Testing
- Bevacizumab, Ipilimumab, Nivolumab
- Where
- Australia
- Volunteers
- 46 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Non Squamous Non-small Cell Lung Cancer, Brain Metastases
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
This is a multi-center phase 3 randomized controlled study to assess the efficacy of Pemetrexed/platinum with or without Bevacizumab on patients with brain metastasis from non-small cell lung cancer(NSCLC) harboring EGFR/ALK wild…
- Conditions
- Non Squamous Non-small Cell Lung Cancer, Brain Metastases, Bevacizumab
- Trial name
- NCT01951482
- Testing
- Pemetrexed/Platinum, Bevacizumab and Pemetrexed/platinum
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Study to assess the effectiveness and safety of SHR 1316, bevacizumab combined with cisplatin/carboplatin for treatment of triple-negative breast cancer brain metastases.
- Trial name
- NCT04303988
- Testing
- SHR-1316, Bevacizumab, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fudan University
HER-2 Positive Breast Cancer
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Purpose: This study is a single-arm, open-label phase II clinical trial testing the hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective, safe, and tolerable among patients with human…
- Trial name
- NCT01305941
- Testing
- Everolimus, Vinorelbine, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
This single-arm, multicenter, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with whole brain radiotherapy on brain metastases in patients with HER-2 positive breast cancer.
- Trial name
- NCT01363986
- Testing
- trastuzumab [Herceptin]
- Where
- 16 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Brain Neoplasms
- Trial name
- NCT00076856
- Testing
- Temozolomide
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs, such as riluzole, may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT01018836
- Testing
- riluzole, whole-brain radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-small Cell Lung Carcinoma (NSCLC)
A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
The purpose of this study is to establish the intracranial efficacy of single agent capmatinib in the population of treatment-naïve or pretreated with one or two prior lines of systemic therapies for advanced stage Non Small-Cell…
- Trial name
- NCT04460729
- Testing
- Capmatinib
- Sponsor
- Novartis Pharmaceuticals
Metastatic Malignant Neoplasm to Brain
Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis
This phase I pilot study aims to define the safety of a combined treatment of bevacizumab and whole brain radiation therapy for the treatment of patients with brain metastasis of solid tumors.
- Trial name
- NCT01332929
- Testing
- Bevacizumab
- Where
- 6 sites in France
- Volunteers
- 21 people
- Sponsor
- Centre Francois Baclesse
Brain Metastases, Non-small Cell Lung Cancer
Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
This is a randomized, double blind placebo controlled study to evaluate safety and efficacy of lucanthone administered as an adjunct to patients receiving whole brain radiation therapy (WBRT) as primary treatment for brain…
- Trial name
- NCT02014545
- Testing
- Lucanthone
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Metastatic Renal Cell Carcinoma
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).
- Trial name
- CABRAMET (NCT03967522)
- Testing
- Cabozantinib
- Where
- 12 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Leon Berard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.